Search results
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
Zacks· 19 hours agoFree Report) lately with too much selling pressure. This is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. Usually, a
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Zacks· 19 hours agoFree Report) is expected to reveal quarterly earnings of $10.14 per share, indicating an increase of 0.5% compared to the year-ago period. Analysts forecast revenues of $3.19 billion, representing ...
EXEL vs. REGN: Which Stock Is the Better Value Option?
Zacks· 5 days agoBiomedical and Genetics stocks have likely encountered both Exelixis (EXEL Quick QuoteEXEL - Free Report) and Regeneron (REGN Quick QuoteREGN - Free Report) . There are plenty ...
Regeneron (REGN) Reports Next Week: What You Should Expect
Zacks· 5 days agoFree Report) is expected to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended March 2024. The stock might ...
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday...
Zacks· 5 days agoApril 25, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the...
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Zacks via Yahoo Finance· 5 days agoToday's Research Daily features new research reports on 16 major stocks, including Danaher...
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 4 days agoSRPT will report first-quarter earnings results on May 1. argenx SE ARGX has an Earnings ESP of...
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Zacks via Yahoo Finance· 4 days agoSanofi Price and Consensus Sanofi price-consensus-chart | SanofiQuote A better-ranked biotech stock...
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Zacks· 5 days agoFree Report) and Bristol Myers Squibb (BMY Quick QuoteBMY - Free Report) . Other regulatory and acquisition updates were in focus as well. Biogen, BMY’s Q1 Earnings: Biogen reported first-quarter ...
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Zacks· 6 days agoRoche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.